Newsroom

July 2020

• 
  Story Jul 23, 2020 Discovery

  Helping clinical trial patients during a lockdown

  Yan Zhao talks about how her team in China responded to an emerging public health crisis.

• Press release Jul 23, 2020

  Novartis announces Phase III study of Jakavi® in chronic graft-versus-host disease met primary and key secondary endpoints

  Jakavi® demonstrated superior overall response rate in patients with chronic graft-versus-host disease (GvHD) compared to best available therapy, building on previous positive findings in acute GvHD1…
• Ad hoc release Jul 21, 2020

  Novartis delivered strong H1 performance. FY 2020 guidance confirmed at higher end for core operating income and lower end for sales.

  Due to COVID-19 first half results are more representative of underlying performance than Q2, sales growth of 6%  (cc1, +3% USD) and core¹ operating income growth of 19% (cc, +14% USD):…
• Ad hoc release Jul 21, 2020

  Novartis erzielte im ersten Halbjahr eine starke Performance. Die Jahresprognose 2020 für das operative Kernergebnis bzw. den Umsatz wurde am oberen bzw. unteren Ende früherer Voraussagen bestätigt.

  Aufgrund von COVID-19 sind die Ergebnisse des ersten Halbjahres repräsentativer für die zugrundeliegende Performance als die Ergebnisse des zweiten Quartals; Umsatzwachstum von 6% (kWk1, +3% USD…
• Ad hoc release Jul 21, 2020

  Novartis réalise une excellente performance au S1. Prévisions pour 2020 confirmées dans le haut de la fourchette pour le résultat opérationnel core et dans le bas pour le chiffre d’affaires.

  En raison du Covid-19 les résultats du S1 sont plus représentatifs de la performance sous-jacente que ceux du T2, croissance de 6% (tcc1, +3% USD) du chiffre d’affaires et de 19% (tcc, +14% USD) du…
• Press release Jul 16, 2020

  Novartis launches first-of-its-kind not-for-profit portfolio of medicines for symptomatic treatment of COVID-19

  Portfolio of 15 generic and over-the-counter (OTC) medicines from Sandoz division addresses urgent unmet needs of low- and lower-middle-income countries to treat patients with COVID-19…
• Press release Jul 10, 2020

  Novartis Phase III IRIDIUM data in Lancet Respiratory Medicine show benefit of Enerzair® Breezhaler® (QVM149), the first-in-class inhaled LABA/LAMA/ICS combination in uncontrolled asthma

  Once-daily Enerzair® Breezhaler® (QVM149; IND/GLY/MF) was superior to once-daily IND/MF (QMF149) in improving the lung function of patients whose asthma is uncontrolled with LABA/ICS standard-of-care…
• 
  Story Jul 09, 2020 Access to Healthcare

  Cancer didn’t stop for COVID-19

  Myriam Mendila describes how Novartis continued supporting cancer patients and healthcare professionals during the pandemic.

• Press release Jul 07, 2020

  Novartis receives EC approval for Enerzair® Breezhaler®, including the first digital companion (sensor and app) that can be prescribed alongside a treatment for uncontrolled asthma in the EU

  European Commission approves once-daily Enerzair® Breezhaler® (QVM149; IND/GLY/MF) in the EU, the first-in-class LABA/LAMA/ICS fixed-dose combination for patients whose asthma is uncontrolled with…
• In The News Jul 07, 2020

  Pharma’s pandemic response could help attract tech talent

  Novartis Chief Digital Officer Bertrand Bodson talked to FiercePharma about pharma’s COVID-19 pandemic reputation boost with potential tech hires.
• Ad hoc release Jul 03, 2020

  Novartis resolves legacy litigation matters, finalizing settlement of speaker program litigation with Government in the US and positioning company for the future by fully scaling its next-generation digital engagement technologies

  Company finalizes USD 678 million settlement relating to suit challenging speaker programs and other promotional events conducted from 2002 through 2011 in the US as well as USD 51.25 million related…
• Press release Jul 01, 2020

  Sandoz reviewing options after Federal Circuit upholds lower court ruling in biosimilar Erelzi® case

  Sandoz evaluating next steps, including potential appeal to US Supreme Court Ruling continues to prevent launch of important, affordable treatment option for US patients affected by chronic…